Does treatment assignment influence the prognosis of patients with symptomatic severe aortic stenosis?

Table 4 Variables independently related to adverse events in the total study populations (368 patients): Cox proportional hazard univariate and multivariate analysis

Variables	Values of patients with vs without events	HR univariate analysis	CI	p	HR multivariate analysis	CI	p
LV ejection fraction (%)	44 ± 14 vs 52 ± 13	0.96	0.95-0.98	&0.001	0.98	0.96-0.99	0.003
History of heart failure (%)	87 vs 66	1.65	1.28-2.13	&0.001	2.25	1.16-4.34	0.02
GFR (ml/min/1.73/m²)	43 ± 24 vs 63 ± 27	0.98	0.97-0.99	&0.001	0.98	0.97-0.99	0.01
Absolute contraindication to AVR (%)	57 vs 27	3.58	2.16-5.94	&0.001	2.39	1.35-4.22	0.003
Treatment assignment for AS	-	2.01	1.62-2.62	&0.001	1.82	1.10-3.25	&0.001
Age (year)	83 ± 8 vs 77 ± 9	1.02	1.01-1.03	0.004	1.05	0.99-1.09	0.07
NYHA functional class (1–4)	2.8 ± 0.7 vs 2.5 ± 0.07	2.02	1.41-2.90	&0.001	1.05	0.81-1.36	0.69
Charlons co-morbidity index	3.9 ± 1.7 vs 2.7 ± 1.8	1.29	1.18-1.42	&0.001	1.25	0.90-1.57	0.60
Katz score	4.1 ± 1.8 vs 3.1 ± 1.9	1.33	1.11-1.55	&0.001	1.31	0.85-1.62	0.52
Aortic valve area (cm²/m²)	0.61 ± 0.18 vs 0.69 ± 0.20	1.44	0.45-4.41	0.52	0.18	0.01-2.82	0.22
Peripheral artery disease (%)	10 vs 3	3.63	1.32-9.99	0.01	2.36	0.71-7.84	0.16
COPD (%)	36 vs 18	2.48	1.45-4.25	0.01	1.02	0.36-2.84	0.97
Cancer (%)	8 vs 2	1.90	1.11-3.25	0.02	1.07	0.49-2.33	0.87
EuroSCORE (points)	34 ± 22 vs 22 ± 18	1.03	1.02-1.04	&0.001	0.99	0.98-1.01	0.63
ACEi/ARB (%)	49 vs 66	0.48	0.28-0.81	0.006	0.56	0.31-1.01	0.08
Beta-blockers (%)	22 vs 37	0.48	0.26-0.88	0.02	0.57	0.29-1.15	0.12

AS = aortic stenosis; AVR = aortic valve replacement; COPD = chronic obstructive pulmonary disease; GFR = glomerular filtration rate; LV = left ventricular; NYHA = New York Heart Association.

ISSN: 1476-7120